Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
6 hedge funds and large institutions have $292K invested in Reviva Pharmaceuticals Warrants in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
10.12% more ownership
Funds ownership: 0% → 10.12% (+10%)
3% more capital invested
Capital invested by funds: $285K → $292K (+$7.24K)
14% less funds holding
Funds holding: 7 → 6 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$3.54K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10K |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$5.05K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
BlueCrest Capital Management
St Helier,
Jersey
| $239K | +$3.54K | +16,250 | +1% |
|
2
Walleye Capital
New York
| $17K | – | – | – |
|
|
AI
3
Arena Investors
Purchase,
New York
| $16.2K | – | – | – |
|
4
Walleye Trading
New York
| $13K | – | – | – |
|
|
AA
5
AQR Arbitrage
Greenwich,
Connecticut
| $6K | -$5.05K | -23,135 | -41% |
|
|
6
UBS Group
Zurich,
Switzerland
| $1K | +$1.41K | +6,470 | +1,501% |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$10K | -57,064 | Closed |
|
RVPHW Hedge Fund Activity: Q3 2022 in Review
6 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q3 2022, worth a combined $292K — up 2.5% from $285K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RVPHW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was BlueCrest Capital Management, adding an estimated $3.54K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $10K sold.
- 6 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q3 2022, down from 7 in Q2 2022.
- Funds reported $292K of Reviva Pharmaceuticals Warrants stock for Q3 2022, up 2.5% quarter-over-quarter.
- 0 funds opened new Reviva Pharmaceuticals Warrants positions in Q3 2022 and 1 closed out, a net change of -1 holder.
- The largest Reviva Pharmaceuticals Warrants buyer in Q3 2022 was BlueCrest Capital Management, an estimated $3.54K added.
- The largest Reviva Pharmaceuticals Warrants seller in Q3 2022 was Susquehanna International Group, an estimated $10K sold.
Based on aggregated 13F filings for Q3 2022.